IOB - Delayed Quote EUR

Grifols, S.A. (0RDV.IL)

Compare
6.66
-0.03
(-0.37%)
At close: January 29 at 2:35:29 PM GMT
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
7,006,119.00
6,591,977.00
6,063,967.00
4,933,118.00
5,340,038.00
Cost of Revenue
4,275,268.00
4,097,406.00
3,832,437.00
2,970,522.00
3,084,873.00
Gross Profit
2,730,851.00
2,494,571.00
2,231,530.00
1,962,596.00
2,255,165.00
Operating Expense
1,714,014.00
1,758,913.00
1,529,328.00
1,400,087.00
1,279,832.00
Operating Income
1,016,837.00
735,658.00
702,202.00
562,509.00
975,333.00
Net Non Operating Interest Income Expense
-696,186.00
-534,538.00
-444,464.00
-256,151.00
-241,618.00
Other Income Expense
35,737.00
22,898.00
103,519.00
44,095.00
144,914.00
Pretax Income
356,388.00
224,018.00
361,257.00
350,453.00
878,629.00
Tax Provision
132,086.00
43,349.00
90,111.00
85,126.00
169,639.00
Net Income Common Stockholders
161,491.00
59,315.00
208,279.00
188,726.00
618,546.00
Diluted NI Available to Com Stockholders
161,491.00
59,315.00
208,279.00
188,726.00
618,546.00
Basic EPS
0.24
0.09
0.31
0.27
0.90
Diluted EPS
0.24
0.09
0.31
0.27
0.90
Basic Average Shares
679,629.20
679,756.29
679,805.14
681,556.94
685,515.74
Diluted Average Shares
679,629.20
679,756.29
679,805.14
681,556.94
685,515.74
Total Operating Income as Reported
1,092,489.00
799,398.00
805,680.00
595,064.00
996,132.00
Total Expenses
5,989,282.00
5,856,319.00
5,361,765.00
4,370,609.00
4,364,705.00
Net Income from Continuing & Discontinued Operation
161,491.00
59,315.00
208,279.00
188,726.00
618,546.00
Normalized Income
186,615.68
91,490.52
207,135.23
205,113.54
566,939.16
Interest Income
--
62,326.00
33,859.00
11,551.00
8,021.00
Interest Expense
677,708.00
516,060.00
444,543.00
233,813.00
222,921.00
Net Interest Income
-696,186.00
-534,538.00
-444,464.00
-256,151.00
-241,618.00
EBIT
1,034,096.00
740,078.00
805,800.00
584,266.00
1,101,550.00
EBITDA
1,467,068.00
1,181,996.00
1,213,664.00
944,033.00
1,423,083.00
Reconciled Cost of Revenue
4,275,268.00
3,762,627.00
3,512,630.00
2,703,535.00
3,084,873.00
Reconciled Depreciation
432,972.00
441,918.00
407,864.00
359,767.00
321,533.00
Net Income from Continuing Operation Net Minority Interest
161,491.00
59,315.00
208,279.00
188,726.00
618,546.00
Total Unusual Items Excluding Goodwill
-39,920.00
-39,920.00
1,523.00
-21,648.00
63,949.00
Total Unusual Items
-39,920.00
-39,920.00
1,523.00
-21,648.00
63,949.00
Normalized EBITDA
1,506,988.00
1,221,916.00
1,212,141.00
965,681.00
1,359,134.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-14,795.32
-7,744.48
379.23
-5,260.46
12,342.16
12/31/2020 - 1/5/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CUP0.MU Chugai Pharmaceutical Co., Ltd.
20.80
+4.52%
 
AZN.ST AstraZeneca PLC
1,566.00
+0.64%
 
SAN.PA Sanofi
104.40
+0.75%
 
AZN.L AstraZeneca PLC
11,344.00
+0.27%
 
SNY Sanofi
54.34
+0.35%
 
AZN AstraZeneca PLC
70.76
-0.67%
 
AMGN Amgen Inc.
285.42
+0.49%
 
NOVO-B.CO Novo Nordisk A/S
607.30
+0.60%
 
MRK Merck & Co., Inc.
98.82
-0.13%